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Background: Hypertensive patients are particularly at risk of drug-drug interactions resulting from the concomitant 
use of multiple drugs to control their blood pressure. The presence of comorbidities and advancing age are also likely 
to contribute to the use of many drugs, further increasing this risk. Drug related problems such as drug interactions in 
the management of hypertension increase morbidity and mortality but there are limited published data to 
characterize them especially among the African population.  
Objective: To identify and characterize potential drug interactions among adult hypertensive patients attending 
Kenyatta National Hospital. 
Methods: This was a descriptive cross-sectional study done among 313 adult patients between May to July 2016 at 
Kenyatta National Hospital. Ethical approval was sought from the institutional review board. Data on patient 
demographics, clinical characteristics and current prescriptions were extracted from patient records into predesigned 
data collection forms. Potential drug interactions were identified using an online Drug Interactions Checker.  
Results: There was female predominance at 60.7% and the mean age of the study population was 55.2 years (SD 
15.9).  The mean number of drugs per prescription was 5.93 (SD 2.24). The prevalence of potential drug interactions 
was 92.7%. There was an average of 3.5 drug interactions per prescription. Majority (79.2%) of the potential drug 
interactions were categorized as moderate while major and minor interactions accounted for 4.1% and 16.8%, 
respectively. The most prevalent interacting drug pair was enalapril and furosemide (15.3 %). The most frequent 
major interaction found was between enalapril and spironolactone, which is associated with hyperkalaemia.  
Conclusions: There was a high prevalence of potential drug interactions. Prescribers should be encouraged to be 
vigilant during the management of hypertensive patients to avoid overt drug interactions which may compromise 
treatment outcomes and increase the health care costs. 
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1. Introduction 
Drug-drug interaction (DDI) occurs when two or more 
drugs are administered concomitantly and the 
pharmacological effects of one drug are altered by 
another.  The result of the interaction would either 
increase or decrease the effect of the object drug, or 
produce a new and unanticipated effect of either drug 
(Baxter, 2010).  
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DDIs are considered to be beneficial or harmful 
depending on the type of medication, or the indication 
(Reis and Cassiani, 2011). Problems arise when they 
cause an increase in morbidity and mortality, which 
could otherwise have been avoided. The harmful 
consequences of DDIs range from minor morbidities to 
fatal consequences, (Carter et al, 2002) such as 
hyperkalaemia, increased risk of asthma, increased risk 
of rhabdomyolysis or myopathy as well as increased 
risk of gastrointestinal haemorrhage (Bertoli et al, 
2010; Bucsa et al, 2012). 
The avoidance/prevention of DDIs and their potentially 
harmful outcomes is therefore a relevant clinical 
concern as this would decrease risk of avoidable 
adverse drug events in the patients, which in turn 
would decrease healthcare costs and shorten the length 
of hospital stay (Moura et al, 2009). Nonetheless, there 
is scarcity of studies that have attempted to quantify 
this. 
DDIs may go unnoticed during prescribing. One of the 
attempts to address the problem of harmful DDIs has 
been the development of computerized software for 
checking drug interactions such as Medscape Drug 
Interaction Checker, Drug Interactions Checker, 
Micromedex, and LexiComp Interact. These utilities are 
able to detect potential drug interactions and hence 
guide the clinician in prescribing.  
Hypertension is a global challenge with a study by 
Kearney et al projecting an increase to 29% of the 
world’s adult population that will have hypertension by 
2025. The burden of hypertension is even higher in 
economically developing countries than in economically 
developed countries (Kearney et al, 2005). In Kenya, 
studies on hypertension have shown a prevalence of 
22.8% (Joshi et al, 2014). Studies in Africa, Asia and 
South America have shown that the prevalence of DDIs 
is high ranging from 30-80% (Reis and Cassiani, 2011; 
Moura et al, 2009; Lubinga and Uwiduhaye, 2011; 
Kothari and Ganguly 2014; Kigen et al, 2011).  
Hypertensive patients are particularly at risk due to the 
concomitant use of multiple drugs to control their blood 
pressure. The presence of comorbidities and advancing 
age are also likely to contribute to the use of many 
drugs, further increasing their risk of DDIs. 
In Kenya, published studies on DDIs specifically in 
hypertensive patients are unavailable. This study 
sought to identify and characterize potential drug 
interactions among adult hypertensive patients at 
Kenyatta National Hospital (KNH) with an aim of raising 
awareness among physicians and pharmacists on the 
extent of the burden of DDIs among their hypertensive 
patients. 
2. Methods 
2.1 Study site and design 
This was a descriptive cross-sectional study conducted 
among 313 freely consenting hypertensive patients 
aged 18 years and above who were either inpatients in 
medical wards or outpatients at the medical outpatient 
clinic of KNH, the largest National Referral and Teaching 
Hospital in East Africa with a bed capacity of 2000 beds 
distributed in 50 wards.  
2.2 Study population and eligibility criteria 
The study period for enrolment of patients was May to 
July 2016. Adult hypertensive patients of both sexes 
who visited the medical out-patient clinic or were 
admitted to the medical wards during the study period, 
who gave informed consent and whose prescriptions 
had more than one drug prescribed were included in 
the study. Any person who could not communicate 
effectively due to stroke was excluded.  
2.3 Sample size and sampling procedure 
Universal sampling was used whereby all eligible 
participants were included as they were identified. The 
final sample size achieved was 313, which was the 
minimum target sample size as calculated using the 
Fischer’s formula (Daniel and Cross, 2013) with an 
estimated prevalence of DDIs among hypertensive 
patients of 71.5% (Kothari and Ganguly, 2014). From 
the medical outpatient clinic, 54 patients were sampled 
and 259 patients were enrolled from the 8 medical 
wards. 
2.4 Data collection and study variables 
Data on patient demographics, clinical characteristics, 
risk factors for polypharmacy, and current 
prescriptions were collected from the patient files. After 
receiving informed consent from the patients the 
researcher also conducted questionnaire-guided 
interviews at the patient’s convenience.  
The data collected from these interviews included 
patient demographics, risk factors, comorbidities and 
current medications. The interview was conducted in 
the available doctor’s or nurse’s room to ensure privacy. 
2.5 Data analysis 
Data analysis was done using STATA version 13 
statistical software. The drugs prescribed to each 
patient were keyed into the online Drug Interactions 
Checker. The host website is a comprehensive and up to 
date source of drugs online, providing free, peer 
reviewed, accurate and independent data on more than 
24,000 prescription drugs, over the counter medicines 
and natural products. This software classified the drug 
interactions as minor, moderate or major interactions 
and their outcomes.  
Major interactions were defined as highly clinically 
significant where the combination should be avoided 
and the risk outweighed the benefit. Moderate 
interactions were defined as moderately clinically 
significant, with the combination usually avoided and 
only used under special circumstances. Lastly, minor 
interactions were defined as minimally clinically 
significant, where risk should be assessed and either an 
alternative drug considered, steps taken to circumvent 
the risk and/or a monitoring plan instituted. The noted 
drug interactions were classified, coded and recorded in 
terms of severity and the clinical outcome.  
Descriptive statistics as frequencies, percentages, mean, 
standard deviation and range were calculated for the 
various variables and reported. 
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2.6 Ethical considerations 
Ethical clearance was sought from Kenyatta National 
Hospital/ University of Nairobi Ethics and Research 
Committee (KNH/UON-ERC), and approval was granted 
under study reference number KNH-ERC/RR/271. 
Permission to use patient files was sought from 
Kenyatta National Hospital Head of medical records. 
Informed consent was sought from the patients before 
administration of the questionnaires. Information 
obtained from the patients was kept in confidence and 
all data collection forms were coded to also maintain 
confidentiality. In cases of identified major DDIs, the 
prescriber was notified and a safer alternative 
recommended. The KNH reporting form for such 
interactions was filled and submitted to facilitate follow 
up.  
3. Results  
A total of 313 participants were included in the study. 
The mean age of the participants was 55.2 years (SD 
15.9). The age ranged between 18 and 90 years but 
majority were above 38 years (Table 1). 
 
Table 1: Characteristics of study participants 
Variable Frequency(n) Percentage (%) 
Gender 
Male 
Female  
 
123 
190 
 
39.3 
60.7 
Clinical setting 
Inpatient 
Outpatient  
 
259 
54 
 
82.8 
17.2 
Age Category (years) 
18-27 
28-37 
38-47 
48-57 
58-67 
68-77 
>78 
Mean ± SD 
Range  
 
19 
29 
46 
76 
64 
55 
24 
 
 
 
6.1 
9.3 
14.7 
24.3 
20.5 
17.6 
7.7 
55.2 ± 15.9 
18,90 
Number of drugs prescribed per patient 
2-5 
6-9 
>9 
131 
163 
19 
41.9 
52.1 
6.1 
 
The mean number of drugs per prescription was 5.93 
(SD 2.24) and ranged from 2 to 16.  Some of the 
predominant classes of drugs prescribed were calcium 
channel blockers (55%), angiotensin converting enzyme 
inhibitors/ angiotensin II receptor blockers (54%), loop 
diuretics (37.1%) and antibiotics (37.1%). 
There were a total of 1086 DDIs identified in the 313 
prescriptions, translating to approximately 3.5 DDIs per 
patient. These ranged from a minimum of 1 to a 
maximum of 12 per patient. Two hundred and ninety 
prescriptions (92.7%) had at least one DDI while 23 
(7.3%) did not have any DDI (Figure 1). 
The overall prevalence of moderate drug interactions 
was 88.5%, while the prevalence of minor and major 
interactions was 36.4% and 11.8, respectively. On 
average, there were 0.1 major, 2.7 moderate and 0.6 
minor DDIs per patient. The highest number of major 
and moderate interactions seen in a patient was 2 and 
10, respectively. Most prescriptions had moderate 
interactions only (49.8%), followed by prescriptions 
with both moderate and minor interactions with a 
prevalence of 27.5% as seen in Figure 1. 
Overall, the predominant drug interacting pair was 
enalapril + furosemide (n= 48, 15.3%) as shown in 
Table 2. It was followed by omeprazole + furosemide, 
carvedilol + furosemide, omeprazole + nifedipine, 
insulin + furosemide and nifedipine + atorvastatin with 
prevalence of 38(12.1%), 37(11.8%), 37(11.8%), 
32(10.2%) and 27 (1.9%) respectively.  
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Figure 1: Prevalence of Drug Interactions 
  
Table 2: Most prevalent interacting drug pairs and their potential outcomes 
Drug pair n (%) 
Severity of Potential 
Interaction 
Potential Outcome 
Enalapril + Furosemide 48(15.3) Moderate  Hypotension  
Omeprazole + Furosemide 38(12.1) Moderate Hypomagnesemia 
Carvedilol + Furosemide 37(11.8) Moderate Hypotension 
Omeprazole + Nifedipine 37(11.8) Minor  Hypotension, bradicardia, edema, 
dyspnoea, confusion, headache  
Insulin + Furosemide 32(10.2) Moderate  Hyperglycaemia  
Atorvastatin + Nifedipine 27(8.6) Moderate Increased risk of rhabdomyolysis 
Enalapril + Enoxaparin 22(7.0) Moderate Hyperkalaemia 
Enalapril + Insulin 21(6.7 Moderate Hypoglycaemia 
HCTZ + Insulin 20(6.4) Moderate Hyperglycaemia 
Carvedilol + Nifedipine 19(6.1) Moderate Hypotension 
Carvedilol + Aspirin 19(6.1) Minor Decreased antihypertensive effect 
HCTZ + Amlodipine 18(5.8) Minor Hypotension 
Hydralazine + Furosemide 17(5.4) Minor Increased diuretic effect 
Aspirin + Furosemide 17(5.4) Minor Decreased diuretic effect 
Enalapril + Metformin 17(5.4) Moderate Hypoglycaemia 
Enalapril + Aspirin 17(5.4) Moderate Decreased antihypertensive effect 
Insulin + Carvedilol 17(5.4) Moderate Hypoglycaemia 
Ceftriaxone + Furosemide 16(5.1) Moderate Nephrotoxicity 
Omeprazole + HCTZ 16(5.1) Moderate Hypomagnesemia 
Losartan + Aspirin 16(5.1) Moderate Decreased antihypertensive effect 
Enalapril + HCTZ 15(4.8) Moderate Hypotension 
Enoxaparin + Spironolactone 15(4.8) Moderate Hyperkalaemia 
Losartan + Insulin 15(4.8) Moderate Hypoglycaemia 
Carvedilol + Spironolactone 15(4.8) Moderate Hypotension 
 
Furosemide and enalapril were the most common drugs 
implicated in DDIs. They were present in 310 and 239 
interacting drug pairs, respectively (Figure 2). 
The most prevalent major drug interacting pair was 
enalapril + spironolactone (n=23, 7.4%) as shown in 
Table 3.  
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The other common major interactions were enalapril + 
trimethoprim and salbutamol + carvedilol, potentially 
causing hyperkalaemia and bronchospasms. 
 
 
        Figure 2: Common Drugs Implicated in DDIs 
 
  Table 3:  Prevalence of major interacting drug pairs and their potential outcomes 
Drug pair n (%) Severity of 
Interaction 
Potential Outcome  
Enalapril + spironolactone 23 (7.4) Major Hyperkalaemia 
Enalapril + trimethoprim 4 (1.3) Major  Hyperkalaemia  
Salbutamol + carvedilol 4 (1.3) Major  Bronchospasms 
Enalapril + KCl 1 (0.3) Major Hyperkalaemia 
Formoterol + Carvedilol 2 (0.6) Major Bronchospasms 
Spironolactone + Losartan 3 (1.0) Major Hyperkalaemia 
Enalapril + Losartan 1 (0.3) Major Hyperkalaemia 
Nimodipine + Carbamazepine 1 (0.3) Major Decreased antihypertensive effect 
Methyldopa + Carvedilol 2 (0.6) Major Hypertensive crises 
Losartan + Trimethoprim 1 (0.3) Major Hyperkalaemia 
Enalapril + Allopurinol 1 (0.3) Major Risk of infection, hypersensitivity 
reactions 
Amlodipine + Simvastatin 1 (0.3) Major Rhabdomyolysis 
 
4.0 Discussion 
The prevalence of potential drug interactions was  
92.7% which is  much higher than that found  by 
Kothari et al (Kothari and Ganguly, 2014). This 
difference could be attributed to the use of a different 
software (Medscape drug interaction checker) to 
identify drug interactions, the differences in the 
inclusion criteria for the study as well as a different 
study setting.  
 The present study reported furosemide and enalapril 
as the most common drugs implicated in DDIs, this was 
consistent with the study by Chelkeba et al in which 
enalapril was the commonest drug followed by 
Furosemide. Some of the other common drugs 
encountered in this study were nifedipine, carvedilol 
and hydrochlorothiazide. Although the most common 
drugs reported to be involved in DDIs in the study by 
Kothari et al were atenolol and aspirin, there was 
similarity in some of the common drugs reported like 
hydrochlorothiazide, enalapril and furosemide (Kothari 
and Ganguly, 2014). 
In the present study, enalapril + furosemide was the 
most common interacting drug pair this was a similar 
finding reported by Chelkeba et al(Chelkeba et al, 
2013). In the study by Kothari, the most common 
interacting drug pair reported was atenolol + 
amlodipine, but less common was enalapril + 
furosemide (Kothari and Ganguly, 2014). The 
implication of this finding is that although these drugs 
are commonly combined, patients must still be 
monitored for any signs of hypotension, decreased 
diuretic and antihypertensive effect and also 
hypokalaemia. Another study had a combination of a 
loop diuretic + ACE inhibitor and loop diuretic + NSAID  
as the most frequently occurring interacting drug pairs 
involving antihypertensive drugs (Lubinga and 
Uwiduhaye, 2011). Digoxin + furosemide was reported 
to be the predominant drug interaction in another study 
(Moura et al, 2009).   
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In the present study, the most frequently occurring 
major interaction was enalapril + spironolactone, this 
was consistent with the study by Chelkeba et al 
(Chelkeba et al, 2013). Another major interaction that 
was reported in the present study was amlodipine + 
simvastatin, this was consistent with the study by Bucsa 
et al in which it was the most prevalent major 
interaction reported (Bucsa et al, 2012). The present 
study also reported a drug combination between 
salbutamol + carvedilol in 4 (1.3%) patients. This 
finding was similar to that by Bertoli et al that reported  
a combination of salbutamol + carvedilol  in 2 out of 200  
patients,  which  was also considered a major 
interaction with a potential outcome of bronchospasms 
(Bertoli et al, 2010).  
Other drug combinations reported in the present study 
that were similar to the study by Bertoli et al were ACE 
inhibitor + antidiabetic with a potential outcome of 
hypoglycaemia, ACE inhibitor + potassium wasting 
diuretic with a potential outcome of hypotension and 
potassium wasting diuretic + corticosteroid that had a 
potential outcome of hypokalaemia. The implication of 
these findings is that although these drugs are 
commonly prescribed, patients must still be monitored 
for any signs of hypoglycaemia, hypotension and 
hypokalaemia. 
5.0 Conclusion  
There was high prevalence of potential DDIs. The 
predicted clinical implications of these interactions 
ranged from major ones such as hyperkalaemia and 
bronchospasms, moderate ones such as hypoglycaemia 
and hypokalaemia and minor ones such as decreased 
antihypertensive and diuretic effects. The implication of 
this finding would be the need to promptly detect such 
drug interactions and thus avoid any associated 
negative outcomes or monitor patients with caution. 
This can be done by use of a computerized software 
system that would aid in monitoring the patients 
effectively. Secondly, deployment of clinical pharmacists 
in all clinical areas will enhance vigilance and aid in 
detection of clinically relevant drug interactions which 
would decrease the risks involved as well as improve 
the quality of prescribing thus enhancing safer and the 
best management in the patient. The study design could 
only provide the prevalence of potential DDIs and not 
the actual outcomes of DDIs, which could form the 
subject for future studies.  
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